Table 2.
Results of binary regression test on baseline measured parameters to predict a PSA reduction of ≥ 50% 4 weeks after receiving three cycles of an intense PSMA-RLT every 4 weeks
| Basal parameters | Therapy response | ||
|---|---|---|---|
| P value | Odd ratio | 95% CI | |
| Age | 0.54 | 0.97 | 0.91–1.05 |
| *PSA | 0.45 | 0.79 | 0.43–1.46 |
| ECOG score | 0.51 | 0.46 | 0.05–4.68 |
| Karnofsky score | 0.89 | 1.00 | 0.93–1.08 |
| Pretreatments: | |||
| Enzalutamide/abiraterone | 0.63 | 1.34 | 0.41–4.37 |
| Docetaxel/cabazitaxel | 0.66 | 0.79 | 0.25–2.37 |
| Xofigo® | 0.36 | 0.59 | 0.19–1.80 |
| Hb | 0.01 | 1.51 | 1.09–2.09 |
| Thrombocyte | 0.33 | 1.00 | 0.99–1.01 |
| *Leucocyte | 0.32 | 7.13 | 0.15–340.3 |
| *Creatinine | 0.23 | 21.89 | 0.15–3204.2 |
| *LDH | 0.97 | 0.94 | 0.05–17.92 |
| *AP | 0.23 | 0.35 | 0.06–1.92 |
| Localizations of metastasis: | |||
| Bone only | 0.39 | 0.61 | 0.19–1.92 |
| Lymph node only | 0.62 | 1.47 | 0.33–6.51 |
| Bone + lymph node | 0.97 | 0.98 | 0.35–2.74 |
| Liver | 0.60 | 1.44 | 0.24–8.52 |
| Lung | 0.99 | 0.00 | # |
CI confident interval, PSA prostatic specific antigen, Hb hemoglobin, LDH lactate dehydrogenase, AP alkaline phosphatase; (*) data with no Gaussian distribution and log10-transformd for analysis; (#) not calculable; statistically significant results are marked in red